Citations

Clear

203 citation(s) found for "Steven, Alberts".

Marine omega‐3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance)
Song, Mingyang , Hull, Mark A. , Shi, Qian , Giovannucci, Edward L. , Blarigan, Erin L. Van , Meyerhardt, Jeffrey A. , Zemla, Tyler J, Limburg, Paul J. , Meyerhardt, Jeffrey A , Shi, Qian , Song, Mingyang , Ou, Fang‐Shu , Zemla, Tyler , Alberts, Steven R. , Sinicrope, Frank A. , Chan, Andrew T.

Mayo Clinic

International Journal of Cancer | January 9, 2019 | Volume: 145 | Issue: 2 | Pages: 380-389

10.1002/ijc.32113 | PMID 30623420 Get It

Marine omega‐3 polyunsaturated fatty acids (MO3PUFAs) have anticancer properties and may improve colon cancer survival. However, it remains unknown whether the benefit differs by tumor molecular subtype. We examined data from a phase III randomized trial of FOLFOX or FOLFOX + cetuximab among 1,735 stage III colon cancer patients who completed a dietary questionnaire at enrollment. Multivariable hazard ratios and 95% confidence intervals (CIs) were calculated for the association between MO3PUFA and disease‐free survival (DFS) and overall survival according toKRASandBRAFV600Emutations and DNA mismatch repair (MMR) status. Higher MO3PUFA intake was associated with improved 3‐year DFS forKRASwild‐type tumors (77%vs. 73%; HR: 0.84; 95% CI: 0.67–1.05) but notKRAS‐mutant tumors (64%vs. 70%; HR: 1.30; 95% CI: 0.97–1.73;Pinteraction= 0.02). Similar heterogeneity was found by MMR (Pinteraction= 0.14): higher MO3PUFA was associated with better 3‐year DFS for tumors with deficient MMR (72%vs. 67%) but not proficient MMR (72%vs. 72%). No heterogeneity was found byBRAFV600Emutation. Similar findings were obtained for overall survival. In conclusion, we found a suggestive beneficial association between higher MO3PUFA intake and improved survival among stage III colon cancer patients with wild‐typeKRASand deficient MMR. Given the relatively small number of cases with tumor molecular assessments, further studies, preferably through pooled analyses of multiples cohorts, are needed to validate our findings.
A phase 2, open-label study of rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation.
Hendifar, Andrew , Shroff, Rachna T. , Leichman, Lawrence P., Epelbaum, Ron, Geva, Ravit , Kim, George P., Wolff, Robert A. , Allen, Andrew R., Giordano, Heidi, Raponi, Mitch , Isaacson, Jeffrey D., Rolfe, Lindsey, Vonderheide, Robert H. , Domchek, Susan M. , McWilliams, Robert R. , Alberts, Steven R. , Biankin, Andrew V.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: TPS4161-TPS4161

10.1200/jco.2014.32.15_suppl.tps4161 Get It

SWOG S0809: A phase II trial of adjuvant capecitabine (cap)/gemcitabine (gem) followed by concurrent capecitabine and radiotherapy in extrahepatic cholangiocarcinoma (EHCC) and gallbladder carcinoma (GBCA).
Ben‐Josef, Edgar , Guthrie, Katherine A. , Corless, Christopher L. , Zalupski, Mark M. , Lowy, Andrew M. , Thomas, Charles R., Micetich, Kenneth C., Thomas, Melanie B., Siegel, Abby B. , Blanke, Charles D. , El-Khoueiry, Anthony B. , Alberts, Steven R. , Dawson, Laura Ann

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 4030-4030

10.1200/jco.2014.32.15_suppl.4030 Get It

High-grade neuroendocrine carcinoma of the gastrointestinal tract: A retrospective study.
Smyrk, Thomas C. , Chintakuntlawar, Ashish V. , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e15152-e15152

10.1200/jco.2014.32.15_suppl.e15152 Get It

Survival following stage II/III colon cancer (CC): Accent-based comparison versus matched general population (MGP).
Renfro, Lindsay A. , Haller, Daniel G. , Loprinzi, Charles L. , Twelves, Chris, Group, Adjuvant Colon Cancer Endpoints (ACCENT), Grothey, Axel , Kerr, David , André, Thierry , Cutsem, Eric Van , Saltz, Leonard B. , Labianca, Roberto , Alberts, Steven R. , Schmoll, Hans‐Joachim , Yothers, Greg , Sargent, Daniel J. , Group, Adjuvant Colon Cancer Endpoints (ACCENT)

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3601-3601

10.1200/jco.2014.32.15_suppl.3601 Get It

Overall survival result and outcomes by KRAS, BRAF, andDNA mismatch repair in relation to primary tumor site in colon cancers from a randomized trial of adjuvant chemotherapy: NCCTG (Alliance) N0147.
Yoon, Harry H. , Mahoney, Michelle R., Nelson, Garth D. , Thibodeau, Stephen N. , Goldberg, Richard M. , Sinicrope, Frank A. , Sargent, Daniel J. , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3525-3525

10.1200/jco.2014.32.15_suppl.3525 Get It

Phase 1 dose escalation study of copanlisib (BAY 80-6946) in combination with gemcitabine or gemcitabine-cisplatin in advanced cancer patients.
Renshaw, Frank Gary, Genvresse, Isabelle , Reif, Stefanie , Kaplan, Jennifer A. , Kim, Richard D. , Alberts, Steven R. , Kaplan, Jennifer, Grilley‐Olson, Juneko E.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 2610-2610

10.1200/jco.2014.32.15_suppl.2610 Get It

Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial.
Yoon, Harry H. , Bendell, Johanna C. , Braiteh, Fadi S., Firdaus, Irfan , Philip, Philip Agop, Cohn, Allen Lee, Lewis, Nancy , Anderson, D. Mark , Arrowsmith, Edward, Schwartz, Jonathan D. , Xu, Yihuan, Koshiji, Minori, Anderson, Daniel M., Alberts, Steven R. , Wainberg, Zev A.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 4004-4004

10.1200/jco.2014.32.15_suppl.4004 Get It

Racial differences in KRAS/BRAF mutation rates and survival in colon cancer (NCCTG N0147 [Alliance]).
Yoon, Harry H. , Goldberg, Richard M. , Thibodeau, Stephen N. , Shi, Qian , Alberts, Steven R. , Sargent, Daniel J. , Sinicrope, Frank A.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3536-3536

10.1200/jco.2014.32.15_suppl.3536 Get It

Molecular subtyping of colon cancers and distinct prognostic groups [NCCTG N0147 (Alliance)].
Thibodeau, Stephen N. , Goldberg, Richard M. , Sinicrope, Frank A. , Shi, Qian , Sargent, Daniel J. , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3512-3512

10.1200/jco.2014.32.15_suppl.3512 Get It